220 related articles for article (PubMed ID: 17665889)
1. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
3. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
[TBL] [Abstract][Full Text] [Related]
4. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
Allegretti M; Bertini R; Cesta MC; Bizzarri C; Di Bitondo R; Di Cioccio V; Galliera E; Berdini V; Topai A; Zampella G; Russo V; Di Bello N; Nano G; Nicolini L; Locati M; Fantucci P; Florio S; Colotta F
J Med Chem; 2005 Jun; 48(13):4312-31. PubMed ID: 15974585
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
[TBL] [Abstract][Full Text] [Related]
6. DF2755A, a novel non-competitive allosteric inhibitor of CXCR1/2, reduces inflammatory and post-operative pain.
Lopes AH; Brandolini L; Aramini A; Bianchini G; Silva RL; Zaperlon AC; Verri WA; Alves-Filho JC; Cunha FQ; Teixeira MM; Allegretti M; Cunha TM
Pharmacol Res; 2016 Jan; 103():69-79. PubMed ID: 26592483
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
Sablone MR; Cesta MC; Moriconi A; Aramini A; Bizzarri C; Di Giacinto C; Di Bitondo R; Gloaguen I; Aschi M; Crucianelli M; Bertini R; Allegretti M
Bioorg Med Chem Lett; 2009 Aug; 19(15):4026-30. PubMed ID: 19560921
[TBL] [Abstract][Full Text] [Related]
8. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
9. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
[TBL] [Abstract][Full Text] [Related]
10. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Fan GH; Zebala JA
J Med Chem; 2014 Oct; 57(20):8378-97. PubMed ID: 25254640
[TBL] [Abstract][Full Text] [Related]
12. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
[TBL] [Abstract][Full Text] [Related]
13. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.
Nicholls DJ; Tomkinson NP; Wiley KE; Brammall A; Bowers L; Grahames C; Gaw A; Meghani P; Shelton P; Wright TJ; Mallinder PR
Mol Pharmacol; 2008 Nov; 74(5):1193-202. PubMed ID: 18676678
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
[TBL] [Abstract][Full Text] [Related]
15. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.
Cunha TM; Barsante MM; Guerrero AT; Verri WA; Ferreira SH; Coelho FM; Bertini R; Di Giacinto C; Allegretti M; Cunha FQ; Teixeira MM
Br J Pharmacol; 2008 May; 154(2):460-70. PubMed ID: 18362895
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.
Barsante MM; Cunha TM; Allegretti M; Cattani F; Policani F; Bizzarri C; Tafuri WL; Poole S; Cunha FQ; Bertini R; Teixeira MM
Br J Pharmacol; 2008 Mar; 153(5):992-1002. PubMed ID: 17891165
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
[TBL] [Abstract][Full Text] [Related]
19. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
Russo RC; Garcia CC; Teixeira MM; Amaral FA
Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
Kaur M; Singh D
J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
